At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
Sutentdrug
Likely dose
Sutent 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
In Brief
A Phase 2 clinical trial evaluating Sutent for Non Small Cell Lung Cancer. Completed, enrolled 63 participants across 13 sites.
Detailed Summary
The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedMar 2009
Primary CompletionJul 2012
TodayJul 2026
First PostedMar 19, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 17.3 years ago
Interventions
Sutentdrug
Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.